1-19 of 19
Authors: Roopal Thakkar
Save search
Sort by
Journal Article

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry Open Access

PDF
Edward V Loftus and others
Inflammatory Bowel Diseases, Volume 25, Issue 9, September 2019, Pages 1522–1531, https://doi.org/10.1093/ibd/izz008
Published: 08 February 2019
Journal Article

O-006 Efficacy and Safety of Standard Versus Low Dose Adalimumab Maintenance Therapy as Influenced by Disease Severity in Pediatric Crohn’s Disease Get access

PDF
Jeffrey Hyams and others
Inflammatory Bowel Diseases, Volume 19, Issue suppl_1, 1 December 2013, Pages S3–S5, https://doi.org/10.1097/01.MIB.0000438557.05443.73
Published: 01 December 2013
Journal Article

P-137 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients Get access

PDF
Jean-Frédéric Colombel and others
Inflammatory Bowel Diseases, Volume 19, Issue suppl_1, 1 December 2013, Pages S78–S79, https://doi.org/10.1097/01.MIB.0000438815.88752.30
Published: 01 December 2013
Journal Article

P-139 PYRAMID Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year 5 Get access

PDF
Geert D'Haens and others
Inflammatory Bowel Diseases, Volume 19, Issue suppl_1, 1 December 2013, Page S79, https://doi.org/10.1097/01.MIB.0000438817.73505.50
Published: 01 December 2013
Journal Article

P-138 Sustained Efficacy in Patients with Ulcerative Colitis Treated with Adalimumab: Results from ULTRA 2 Get access

PDF
Subrata Ghosh and others
Inflammatory Bowel Diseases, Volume 19, Issue suppl_1, 1 December 2013, Page S79, https://doi.org/10.1097/01.MIB.0000438816.96376.0b
Published: 01 December 2013
Journal Article

P-141 Association Between Week 8 Mayo Subscores and Hospitalisation Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA1 and ULTRA2 Get access

PDF
Walter Reinisch and others
Inflammatory Bowel Diseases, Volume 19, Issue suppl_1, 1 December 2013, Page S80, https://doi.org/10.1097/01.MIB.0000438819.81129.12
Published: 01 December 2013
Journal Article

P-177 Long-term Safety of Adalimumab in Pediatric Patients with Crohn's Disease Get access

PDF
Robert Baldassano and others
Inflammatory Bowel Diseases, Volume 19, Issue suppl_1, 1 December 2013, Page S97, https://doi.org/10.1097/01.MIB.0000438919.58134.53
Published: 01 December 2013
Journal Article

P-20 Mucosal Healing in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2 Get access

PDF
Geert D’Haens and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Page S21, https://doi.org/10.1097/00054725-201212001-00053
Published: 01 December 2012
Journal Article

P-21 Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2 Get access

PDF
Gert Van Assche and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Pages S21–S22, https://doi.org/10.1097/00054725-201212001-00054
Published: 01 December 2012
Journal Article

P-23 Concomitant Use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis Get access

PDF
James Lewis and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Pages S22–S23, https://doi.org/10.1097/00054725-201212001-00056
Published: 01 December 2012
Journal Article

P-59 Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease Get access

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Pages S39–S40, https://doi.org/10.1097/00054725-201212001-00092
Published: 01 December 2012
Journal Article

P-60 Adalimumab Therapy Reduces Hospitalization Rates in Patients With Ulcerative Colitis Among Initial Responders Get access

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Page S40, https://doi.org/10.1097/00054725-201212001-00093
Published: 01 December 2012
Journal Article

P-58 Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE Get access

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Page S39, https://doi.org/10.1097/00054725-201212001-00091
Published: 01 December 2012
Journal Article

P-61 Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy Get access

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Pages S40–S41, https://doi.org/10.1097/00054725-201212001-00094
Published: 01 December 2012
Journal Article

P-19 Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis Get access

PDF
Jean-Frédéric Colombel and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Pages S20–S21, https://doi.org/10.1097/00054725-201212001-00052
Published: 01 December 2012
Journal Article

P-22 Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately-to-Severely Active Ulcerative Colitis: ULTRA 2 Subanalysis Get access

PDF
Doug Wolf and others
Inflammatory Bowel Diseases, Volume 18, Issue suppl_1, 1 December 2012, Page S22, https://doi.org/10.1097/00054725-201212001-00055
Published: 01 December 2012
Journal Article

Baseline C-reactive protein is associated with disease progression in patients with Crohn's disease: P-34. Get access

PDF
Jean-Frédéric Colombel and others
Inflammatory Bowel Diseases, Volume 17, Issue Suppl_2, 1 December 2011, Page S22, https://doi.org/10.1097/00054725-201112002-00071
Published: 01 December 2011
Journal Article

Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohn's disease: P-35. Get access

PDF
Jean-Frédéric Colombel and others
Inflammatory Bowel Diseases, Volume 17, Issue Suppl_2, 1 December 2011, Pages S22–S23, https://doi.org/10.1097/00054725-201112002-00072
Published: 01 December 2011
Journal Article

Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis: O-7. Get access

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 17, Issue Suppl_2, 1 December 2011, Pages S3–S4, https://doi.org/10.1097/00054725-201112002-00008
Published: 01 December 2011